United States

Sumitomo Chemical Co Ltd (4005.T)

4005.T on Tokyo Stock Exchange

21 Sep 2018
Change (% chg)

¥20 (+3.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.
Wednesday, 14 Feb 2018 12:20am EST 

Feb 14 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it filed patent infringement lawsuits jointly with its U.S. subsidiary, Sunovion Pharmaceuticals Inc. on February 13(U.S. Eastern Time) in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd. and in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC regarding their submissions of Abbreviated New Drug Applications for generic copies of LATUDA®(lurasidone HCl tablets).  Full Article

Sumitomo Chemical to merge with unit CO2 M-Tech
Tuesday, 6 Feb 2018 01:49am EST 

Feb 6(Reuters) - Sumitomo Chemical Co Ltd <4005.T>:Says it plans to merge with a wholly owned subsidiary CO2 M-Tech Co.,LTD.Merger effective April 1.Says CO2 M-Tech will be dissolved after the merger .  Full Article

Sumitomo Dainippon Pharma says result of early-retirement program
Sunday, 24 Dec 2017 09:25pm EST 

Dec 25 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T> ::Says 86 employees took up the offer of the early-retirement program announced on Sept. 27.Effective date of retirement is March 31, 2018.A premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

Sumitomo Chemical Co to buy stake exceeding 80% in Botanical Resources Australia - Nikkei
Tuesday, 21 Nov 2017 04:29pm EST 

Nov 22 (Reuters) - Nikkei::Sumitomo Chemical Co Ltd to buy a stake exceeding 80% in Botanical Resources Australia for about 15 billion yen - Nikkei.  Full Article

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Tuesday, 21 Nov 2017 02:32am EST 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey.  Full Article

Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin
Monday, 30 Oct 2017 03:06am EDT 

Oct 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.Under the Agreement, Poxel SA is entitled to receive an upfront payment of approximately 4.75 billion yen and future potential development milestone payments of up to 2.75 billion yen .  Full Article

Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement
Tuesday, 24 Oct 2017 04:22am EDT 

Oct 24 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR).  Full Article

Nufarm extends agreements with Sumitomo Chemical Co​
Monday, 23 Oct 2017 06:06pm EDT 

Oct 24 (Reuters) - Nufarm Ltd ::Signs long-term extension to a series of global collaboration agreements with Sumitomo Chemical Co​.  Full Article

R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook -R&I
Tuesday, 3 Oct 2017 05:19am EDT 

Oct 3(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I.Rating outlook stable -R&I.  Full Article

Sumitomo Dainippon Pharma to offer early-retirement program
Wednesday, 27 Sep 2017 03:10am EDT 

Sept 27 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:* Says it will offer an early-retirement program to employees, who are above 45 years old and continuous service of above 5 years as of March 31, 2018, and employees is members of manufacturing division as of Sept. 1, 2016 .* Offering period from Nov. 15 to Dec. 15.* Says the employees who take up the offer will retire on March 31, 2018.* The company will provide retirement payment and outplacement support to the retiring employees .  Full Article


Roundup cancer verdict sends Bayer shares sliding

FRANKFURT Bayer shares plunged as much as 14 percent on Monday, losing about $14 billion in value, after newly acquired Monsanto was ordered to pay $289 million in damages in the first of possibly thousands of U.S. lawsuits over alleged links between a weedkiller and cancer. | Video